



**Merck & Co., Inc.
Financial Highlights Package
Fourth Quarter 2011
Table of Contents**

Table 1: GAAP P&L.....	1
Table 1a: GAAP P&L - Current Year and Prior Year by Quarter.....	2
Table 2a: GAAP to Non-GAAP P&L Reconciliation 4Q11	3
Table 2b: GAAP to Non-GAAP P&L Reconciliation Full Year 11	4
Table 2c: GAAP to Non-GAAP P&L Reconciliation 4Q10	5
Table 2d: GAAP to Non-GAAP P&L Reconciliation Full Year 10.....	6
Table 3: Sales - Current Year and Prior Year by Quarter	7
Table 3a: Sales - U.S. / Ex- U.S. 4Q11	8
Table 3b: Sales - U.S. / Ex- U.S. Full Year 11.....	9
Table 3c: Sales - Pharmaceutical Geographic Split.....	10
Table 4: Equity Income / JV Sales / Other (Income) Expense.....	11

MERCK & CO., INC.
CONSOLIDATED STATEMENT OF OPERATIONS - GAAP
(AMOUNTS IN MILLIONS, EXCEPT PER SHARE FIGURES)
(UNAUDITED)

Table 1

	GAAP		% Change	GAAP		% Change
	4Q11	4Q10		Full Year 2011	Full Year 2010	
Sales	\$ 12,294	\$ 12,094	2%	\$ 48,047	\$ 45,987	4%
Costs, Expenses and Other						
Materials and production ⁽¹⁾	4,176	4,440	-6%	16,871	18,396	-8%
Marketing and administrative ^{(1) / (2)}	3,704	3,537	5%	13,733	13,125	5%
Research and development ^{(1) / (2)}	2,419	4,559	-47%	8,467	11,111	-24%
Restructuring costs ⁽³⁾	533	121	*	1,306	985	33%
Equity income from affiliates ⁽⁴⁾	(257)	(171)	50%	(610)	(587)	4%
Other (income) expense, net ^{(1) / (5)}	139	309	-55%	946	1,304	-27%
Income (Loss) Before Taxes	1,580	(701)	*	7,334	1,653	*
Income Tax Provision (Benefit)	37	(201)		942	671	
Net Income (Loss)	1,543	(500)	*	6,392	982	*
Less: Net Income Attributable to Noncontrolling Interests	31	31		120	121	
Net Income (Loss) Attributable to Merck & Co., Inc.	\$ 1,512	\$ (531)	*	\$ 6,272	\$ 861	*
Earnings (Loss) per Common Share Assuming Dilution ⁽⁶⁾	\$ 0.49	\$ (0.17)	*	\$ 2.02	\$ 0.28	*
Average Shares Outstanding Assuming Dilution ⁽⁷⁾	3,069	3,081		3,094	3,120	
Tax Rate ⁽⁸⁾	2.3%	28.7%		12.8%	40.6%	

*100% or greater

(1) Amounts include the impact of acquisition-related costs, restructuring costs and certain other items. See accompanying tables for details.

(2) The fourth quarter and full year of 2010 include a reclassification of certain expenses from marketing and administrative to research and development of \$42 million and \$120 million, respectively.

(3) Represents separation and other related costs associated with restructuring activities under the company's formal restructuring programs.

(4) Primarily reflects equity income from the AstraZeneca LP and Sanofi Pasteur MSD partnerships.

(5) Other (income) expense, net in the full year of 2011 includes a charge of \$500 million related to the resolution of the arbitration proceeding with Johnson & Johnson, a \$136 million gain on the sale of the company's interest in the Johnson & Johnson^oMerck Consumer Pharmaceuticals Company joint venture and a \$127 million gain on the sale of certain manufacturing facilities and related assets. Other (income) expense, net in the full year of 2010 reflects a \$950 million legal reserve, \$200 million of exchange losses due to Venezuelan currency devaluations and \$443 million of income recognized upon AstraZeneca's asset option exercise.

(6) The company calculates earnings per share pursuant to the two-class method which requires the allocation of net income between common shareholders and participating security holders (losses are not allocated). Net income attributable to Merck & Co., Inc. common shareholders used to calculate earnings per common share assuming dilution was \$1,510 million for the fourth quarter of 2011 and was \$6,257 million and \$859 million for the full year of 2011 and 2010, respectively.

(7) Because the company recorded a loss in the fourth quarter of 2010, no potential dilutive common shares were used in the computation of loss per share assuming dilution as the effect would have been anti-dilutive.

(8) The GAAP effective tax rate for the fourth quarter of 2011 was 2.3%. The GAAP effective tax rate for the full year of 2011 was 12.8%, which reflects the net favorable impact of approximately \$700 million related to the settlement of the company's 2002-2005 federal income tax audit. Excluding this item and the other non-GAAP reconciling items detailed in the accompanying tables, the effective tax rates were 19.9% and 23.4% for the fourth quarter and full year of 2011, respectively. The GAAP effective tax rates for the fourth quarter and full year of 2010 were 28.7% and 40.6%, respectively. Excluding the impact of the non-GAAP reconciling items detailed in the accompanying tables, the effective tax rates were 14.1% and 20.0% for the fourth quarter and full year of 2010, respectively.

MERCK & CO., INC.
CONSOLIDATED STATEMENT OF OPERATIONS - GAAP
(AMOUNTS IN MILLIONS, EXCEPT PER SHARE FIGURES)
(UNAUDITED)

Table 1a

	2011					2010					% Change	
	1Q	2Q	3Q	4Q	Full Year	1Q	2Q	3Q	4Q	Full Year	4Q	Full Year
Sales	\$ 11,580	\$ 12,151	\$ 12,022	\$ 12,294	\$ 48,047	\$ 11,422	\$ 11,346	\$ 11,125	\$ 12,094	\$ 45,987	2%	4%
Costs, Expenses and Other												
Materials and production	4,059	4,284	4,352	4,176	16,871	5,216	4,549	4,191	4,440	18,396	-6%	-8%
Marketing and administrative ⁽¹⁾	3,164	3,525	3,340	3,704	13,733	3,222	3,175	3,192	3,537	13,125	5%	5%
Research and development ⁽¹⁾	2,158	1,936	1,954	2,419	8,467	2,051	2,179	2,322	4,559	11,111	-47%	-24%
Restructuring costs	(14)	668	119	533	1,306	288	526	50	121	985	*	33%
Equity income from affiliates	(138)	(55)	(161)	(257)	(610)	(138)	(43)	(236)	(171)	(587)	50%	4%
Other (income) expense, net	622	121	66	139	946	167	(281)	1,108	309	1,304	-55%	-27%
Income (Loss) Before Taxes	1,729	1,672	2,352	1,580	7,334	616	1,241	498	(701)	1,653	*	*
Income Tax Provision (Benefit)	658	(382)	628	37	942	286	461	126	(201)	671		
Net Income (Loss)	1,071	2,054	1,724	1,543	6,392	330	780	372	(500)	982	*	*
Less: Net Income Attributable to Noncontrolling Interests	28	30	32	31	120	31	28	30	31	121		
Net Income (Loss) Attributable to Merck & Co., Inc.	\$ 1,043	\$ 2,024	\$ 1,692	\$ 1,512	\$ 6,272	\$ 299	\$ 752	\$ 342	\$ (531)	\$ 861	*	*
Earnings (Loss) per Common Share Assuming Dilution	\$ 0.34	\$ 0.65	\$ 0.55	\$ 0.49	\$ 2.02	\$ 0.09	\$ 0.24	\$ 0.11	\$ (0.17)	\$ 0.28	*	*
Average Shares Outstanding Assuming Dilution	3,104	3,110	3,091	3,069	3,094	3,141	3,125	3,102	3,081	3,120		
Tax Rate	38.1%	-22.8%	26.7%	2.3%	12.8%	46.4%	37.1%	25.3%	28.7%	40.6%		

Sum of quarterly amounts may not equal year-to-date amounts due to rounding.

*100% or greater

(1) Amounts in 2010 include a reclassification of certain expenses from marketing and administrative to research and development of \$24 million, \$28 million, \$26 million, \$42 million and \$120 million in 1Q, 2Q, 3Q, 4Q and full year, respectively.

MERCK & CO., INC.
CONSOLIDATED STATEMENT OF OPERATIONS
GAAP TO NON-GAAP RECONCILIATION
FOURTH QUARTER 2011
(AMOUNTS IN MILLIONS, EXCEPT PER SHARE FIGURES)
(UNAUDITED)
Table 2a

	GAAP	Acquisition- Related Costs ⁽¹⁾	Restructuring Costs ⁽²⁾	Certain Other Items	Adjustment Subtotal	Non-GAAP
Sales	\$ 12,294				\$ -	\$ 12,294
Materials and production	4,176	1,212	68	7	1,287	2,889
Marketing and administrative	3,704	86	42		128	3,576
Research and development	2,419	244	49		293	2,126
Restructuring costs	533		533		533	-
Equity income from affiliates	(257)				-	(257)
Other (income) expense, net	139	(63)		(1)	(64)	203
Income Before Taxes	1,580	(1,479)	(692)	(6)	(2,177)	3,757
Taxes on Income	37				(711) ⁽³⁾	748
Net Income	1,543				(1,466)	3,009
Less: Net Income Attributable to Noncontrolling Interests	31				-	31
Net Income Attributable to Merck & Co., Inc.	\$ 1,512				\$ (1,466)	\$ 2,978
Earnings per Common Share Assuming Dilution	\$ 0.49					\$ 0.97 ⁽⁴⁾
Average Shares Outstanding Assuming Dilution	3,069					3,069
Tax Rate	2.3%					19.9%

Merck is providing non-GAAP information that excludes certain items because of the nature of these items and the impact they have on the analysis of underlying business performance and trends. Management believes that providing this information enhances investors' understanding of the company's performance. This information should be considered in addition to, but not in lieu of, information prepared in accordance with GAAP.

(1) Amounts included in materials and production costs reflect expenses for the amortization of intangible assets and the amortization of purchase accounting adjustments to inventories recognized as a result of mergers and acquisitions. Amounts included in marketing and administrative expenses reflect integration costs, as well as other costs associated with mergers and acquisitions, such as severance costs which are not part of the company's formal restructuring programs. Amounts included in research and development expenses represent in-process research and development ("IPR&D") impairment charges. Amounts included in other (income) expense, net reflect the favorable resolution of certain reserves assumed in conjunction with the merger.

(2) Amounts primarily include employee separation costs and accelerated depreciation associated with facilities to be closed or divested related to actions under the company's formal restructuring programs.

(3) Includes the favorable impact of certain state tax rate changes that resulted in a net \$40 million reduction of deferred tax liabilities on intangibles established in purchase accounting, as well as the estimated tax impact on the reconciling items.

(4) The company calculates earnings per share pursuant to the two-class method which requires the allocation of net income between common shareholders and participating security holders. Net income attributable to Merck & Co., Inc. common shareholders used to calculate non-GAAP earnings per common share assuming dilution was \$2,973 million for the fourth quarter of 2011.

MERCK & CO., INC.
CONSOLIDATED STATEMENT OF OPERATIONS
GAAP TO NON-GAAP RECONCILIATION
FULL YEAR 2011
(AMOUNTS IN MILLIONS, EXCEPT PER SHARE FIGURES)
(UNAUDITED)
Table 2b

	GAAP	Acquisition- Related Costs ⁽¹⁾	Restructuring Costs ⁽²⁾	Certain Other Items ⁽³⁾	Adjustment Subtotal	Non-GAAP
Sales	\$ 48,047				\$ -	\$ 48,047
Materials and production	16,871	5,137	348	7	5,492	11,379
Marketing and administrative	13,733	278	119		397	13,336
Research and development	8,467	587	138		725	7,742
Restructuring costs	1,306		1,306		1,306	-
Equity income from affiliates	(610)				-	(610)
Other (income) expense, net	946	(63)		235	172	774
Income Before Taxes	7,334	(5,939)	(1,911)	(242)	(8,092)	15,426
Taxes on Income	942				(2,667) ⁽⁴⁾	3,609
Net Income	6,392				(5,425)	11,817
Less: Net Income Attributable to Noncontrolling Interests	120				-	120
Net Income Attributable to Merck & Co., Inc.	\$ 6,272				\$ (5,425)	\$ 11,697
Earnings per Common Share Assuming Dilution	\$ 2.02					\$ 3.77 ⁽⁵⁾
Average Shares Outstanding Assuming Dilution	3,094					3,094
Tax Rate	12.8%					23.4%

Merck is providing non-GAAP information that excludes certain items because of the nature of these items and the impact they have on the analysis of underlying business performance and trends. Management believes that providing this information enhances investors' understanding of the company's performance. This information should be considered in addition to, but not in lieu of, information prepared in accordance with GAAP.

(1) Amounts included in materials and production costs reflect expenses of \$5.0 billion for the amortization of intangible assets and the amortization of purchase accounting adjustments to inventories recognized as a result of mergers and acquisitions, as well as \$118 million of impairment charges on product intangibles. Amounts included in marketing and administrative expenses reflect integration costs, as well as other costs associated with mergers and acquisitions, such as severance costs which are not part of the company's formal restructuring programs. Amounts included in research and development expenses represent in-process research and development ("IPR&D") impairment charges. Amounts included in other (income) expense, net reflect the favorable resolution of certain reserves assumed in conjunction with the merger.

(2) Amounts primarily include employee separation costs and accelerated depreciation associated with facilities to be closed or divested related to actions under the company's formal restructuring programs.

(3) Included in other (income) expense, net is a \$500 million charge related to the resolution of the arbitration proceeding with Johnson & Johnson, a \$136 million gain on the divestiture of the company's interest in the Johnson & Johnson[®]Merck Consumer Pharmaceuticals Company joint venture, as well as a \$127 million gain on the sale of certain manufacturing facilities and related assets.

(4) Includes a net benefit of approximately \$700 million relating to the settlement of the company's 2002-2005 federal income tax audit, the favorable impact of certain foreign and state tax rate changes that resulted in a net \$270 million reduction of deferred tax liabilities on intangibles established in purchase accounting, as well as the estimated tax impact on the reconciling items.

(5) The company calculates earnings per share pursuant to the two-class method which requires the allocation of net income between common shareholders and participating security holders. Net income attributable to Merck & Co., Inc. common shareholders used to calculate non-GAAP earnings per common share assuming dilution was \$11,670 million for 2011.

MERCK & CO., INC.
CONSOLIDATED STATEMENT OF OPERATIONS
GAAP TO NON-GAAP RECONCILIATION
FOURTH QUARTER 2010
(AMOUNTS IN MILLIONS, EXCEPT PER SHARE FIGURES)
(UNAUDITED)
Table 2c

	GAAP	Acquisition- Related Costs ⁽¹⁾	Restructuring Costs ⁽²⁾	Certain Other Items	Adjustment Subtotal	Non-GAAP
Sales	\$ 12,094				\$ -	\$ 12,094
Materials and production	4,440	1,206	105		1,311	3,129
Marketing and administrative	3,537	160	13		173	3,364
Research and development	4,559	2,225	115		2,340	2,219
Restructuring costs	121		121		121	-
Equity income from affiliates	(171)				-	(171)
Other (income) expense, net	309				-	309
(Loss) Income Before Taxes	(701)	(3,591)	(354)	-	(3,945)	3,244
Taxes on Income	(201)				(658) ⁽³⁾	457
Net (Loss) Income	(500)				(3,287)	2,787
Less: Net Income Attributable to Noncontrolling Interests	31				-	31
Net (Loss) Income Attributable to Merck & Co., Inc.	\$ (531)				\$ (3,287)	\$ 2,756
(Loss) Earnings per Common Share Assuming Dilution	\$ (0.17)					\$ 0.88 ⁽⁴⁾
Average Shares Outstanding Assuming Dilution	3,081					3,106
Tax Rate	28.7%					14.1%

Merck is providing non-GAAP information that excludes certain items because of the nature of these items and the impact they have on the analysis of underlying business performance and trends. Management believes that providing this information enhances investors' understanding of the company's performance. This information should be considered in addition to, but not in lieu of, information prepared in accordance with GAAP.

(1) Amounts included in materials and production costs reflect expenses for the amortization of intangible assets and the amortization of purchase accounting adjustments to inventories recognized as a result of the merger. Amounts included in marketing and administrative expenses reflect transaction and integration costs associated with mergers and acquisitions. Amounts included in research and development expenses represent in-process research and development ("IPR&D") impairment charges, including a \$1.7 billion charge to write-down the intangible asset related to vorapaxar.

(2) Amounts primarily include employee separation costs and accelerated depreciation associated with facilities to be sold or closed related to actions under the company's formal restructuring programs.

(3) Represents the estimated tax impact on the reconciling items.

(4) The company calculates earnings per share pursuant to the two-class method which requires the allocation of net income between common shareholders and participating security holders. Net income attributable to Merck & Co., Inc. common shareholders used to calculate non-GAAP earnings per common share assuming dilution was \$2,746 million for the fourth quarter of 2010.

MERCK & CO., INC.
CONSOLIDATED STATEMENT OF OPERATIONS
GAAP TO NON-GAAP RECONCILIATION
FULL YEAR 2010
(AMOUNTS IN MILLIONS, EXCEPT PER SHARE FIGURES)
(UNAUDITED)
Table 2d

	GAAP	Acquisition- Related Costs ⁽¹⁾	Restructuring Costs ⁽²⁾	Certain Other Items ⁽³⁾	Adjustment Subtotal	Non-GAAP
Sales	\$ 45,987				\$ -	\$ 45,987
Materials and production	18,396	6,566	430		6,996	11,400
Marketing and administrative	13,125	379	143		522	12,603
Research and development	11,111	2,441	428		2,869	8,242
Restructuring costs	985		985		985	-
Equity income from affiliates	(587)				-	(587)
Other (income) expense, net	1,304	17		507	524	780
Income Before Taxes	1,653	(9,403)	(1,986)	(507)	(11,896)	13,549
Taxes on Income	671				(2,042) ⁽⁴⁾	2,713
Net Income	982				(9,854)	10,836
Less: Net Income Attributable to Noncontrolling Interests	121				-	121
Net Income Attributable to Merck & Co., Inc.	\$ 861				\$ (9,854)	\$ 10,715
Earnings per Common Share Assuming Dilution	\$ 0.28					\$ 3.42 ⁽⁵⁾
Average Shares Outstanding Assuming Dilution	3,120					3,120
Tax Rate	40.6%					20.0%

Merck is providing non-GAAP information that excludes certain items because of the nature of these items and the impact they have on the analysis of underlying business performance and trends. Management believes that providing this information enhances investors' understanding of the company's performance. This information should be considered in addition to, but not in lieu of, information prepared in accordance with GAAP.

(1) Amounts included in materials and production costs reflect expenses for the amortization of intangible assets and the amortization of purchase accounting adjustments to inventories recognized as a result of the merger. Amounts included in marketing and administrative expenses and other (income) expense, net reflect transaction and integration costs associated with mergers and acquisitions. Amounts included in research and development expenses represent in-process research and development ("IPR&D") impairment charges, including a \$1.7 billion charge to write-down the intangible asset related to vorapaxar.

(2) Amounts primarily include employee separation costs and accelerated depreciation associated with facilities to be sold or closed related to actions under the company's formal restructuring programs.

(3) Included in other (income) expense, net is a \$950 million legal reserve and \$443 million of income recognized upon AstraZeneca's asset option exercise.

(4) Includes a \$391 million tax benefit from changes in a foreign entity's tax rate, a charge of \$147 million associated with a change in tax law enacted as part of U.S. health care reform legislation, as well as the estimated tax impact on the reconciling items.

(5) The company calculates earnings per share pursuant to the two-class method which requires the allocation of net income between common shareholders and participating security holders. Net income attributable to Merck & Co., Inc. common shareholders used to calculate non-GAAP earnings per common share assuming dilution was \$10,673 million for the full year of 2010.

MERCK & CO., INC.
FRANCHISE / KEY PRODUCT SALES
(AMOUNTS IN MILLIONS)

Table 3

	2011					2010					% Change	% Change
	1Q	2Q	3Q	4Q	Full Year	1Q	2Q	3Q	4Q	Full Year	4Q	Full Year
	\$11,580	\$12,151	\$12,022	\$12,294	\$48,047	\$11,422	\$11,346	\$11,125	\$12,094	\$45,987	2	4
TOTAL SALES ⁽¹⁾												
PHARMACEUTICAL ⁽²⁾	9,820	10,360	10,354	10,755	41,289	9,665	9,638	9,523	10,441	39,267	3	5
Cardiovascular												
Zetia	582	592	614	640	2,428	534	564	571	629	2,297	2	6
Vytorin	480	459	469	475	1,882	477	490	485	562	2,014	-16	-7
Integrilin	64	56	53	57	230	70	70	63	63	266	-9	-14
Diabetes & Obesity												
Januvia	739	779	846	960	3,324	511	600	600	675	2,385	42	39
Janumet	305	321	350	386	1,363	201	218	247	288	954	34	43
Diversified Brands												
Cozaar / Hyzaar	426	406	404	427	1,663	782	485	423	415	2,104	3	-21
Zocor	127	107	110	111	456	116	117	114	121	468	-8	-3
Propecia	106	112	112	117	447	100	113	109	124	447	-6	0
Claritin Rx	120	65	55	74	314	98	58	53	86	296	-14	6
Remeron	60	57	65	59	241	51	59	50	62	223	-5	8
Vasotec / Vaseretic	57	59	57	58	231	59	63	69	64	255	-9	-10
Proscar	60	53	58	52	223	58	56	58	44	216	18	3
Infectious Disease												
Isentress	292	337	343	387	1,359	232	267	278	313	1,090	24	25
PegIntron	166	154	163	175	657	186	185	168	198	737	-12	-11
Candidas	158	168	150	164	640	153	150	135	174	611	-6	5
Primaxin	136	136	124	119	515	159	158	135	158	610	-25	-16
Invanz	87	103	107	110	406	75	83	91	113	362	-3	12
Avelox	106	61	59	95	322	106	59	59	92	316	3	2
Noxafil	55	56	61	59	230	49	50	52	48	198	24	16
Crixivan / Stocrin	45	50	56	42	192	52	48	49	58	206	-28	-7
Rebetol	53	48	38	36	174	56	55	55	54	221	-34	-21
Victrelis	1	21	31	87	140	0	0	0	0	0	*	*
Neurosciences & Ophthalmology												
Maxalt	173	131	156	178	639	135	133	133	149	550	20	16
Cosopt / Trusopt	114	122	124	117	477	115	123	114	131	484	-11	-1
Oncology												
Temodar	248	234	223	230	935	274	271	254	266	1,065	-13	-12
Emend	87	120	98	114	419	84	93	91	110	378	4	11
Intron A	49	47	47	51	194	54	51	50	54	209	-5	-7
Respiratory & Immunology												
Singular	1,328	1,354	1,336	1,461	5,479	1,165	1,258	1,215	1,349	4,987	8	10
Remicade	753	842	561	511	2,667	674	669	661	710	2,714	-28	-2
Nasonex	373	323	266	325	1,286	320	338	259	303	1,219	7	5
Clarinex	155	209	128	129	621	164	191	131	138	623	-6	0
Arcoxia	114	100	108	110	431	95	95	94	115	398	-4	8
Simponi	54	75	74	61	264	10	18	27	42	97	45	*
Asmanex	60	47	42	57	206	51	56	48	53	208	7	-1
Proventil	42	37	38	38	155	57	55	43	55	210	-31	-26
Dulera	13	25	22	37	96	0	0	2	6	8	*	*
Vaccines												
Gardasil	214	277	445	274	1,209	233	219	316	221	988	24	22
ProQuad, M-M-R II and Varivax	244	291	391	276	1,202	319	340	434	285	1,378	-3	-13
RotaTeq	125	148	184	195	651	93	139	119	169	519	15	25
Pneumovax	79	64	133	222	498	51	59	110	156	376	43	33
Zostavax	24	122	108	78	332	95	18	23	107	243	-27	37
Women's Health & Endocrine												
Fosamax	208	221	215	211	855	230	241	220	234	926	-10	-8
NuvaRing	142	154	159	168	623	135	145	134	145	559	16	12
Follistim AQ	133	143	129	126	530	134	137	119	138	528	-9	0
Implanon	60	81	80	74	294	51	51	64	71	236	3	25
Cerazette	59	66	74	69	268	55	49	56	49	209	42	28
Other Pharmaceutical ⁽³⁾	744	927	888	953	3,521	946	941	942	1,044	3,879	-9	-9
ANIMAL HEALTH	758	802	826	868	3,253	709	731	687	815	2,941	6	11
CONSUMER CARE ⁽²⁾	517	541	421	361	1,840	489	544	409	381	1,823	-5	1
Claritin OTC	167	134	118	92	511	136	167	120	103	526	-11	-3
Other Revenues ⁽⁴⁾	486	448	421	310	1,666	559	433	506	457	1,956	-32	-15
Astra	322	306	299	256	1,184	364	241	345	302	1,252	-15	-5

* 100% or greater

Sum of quarterly amounts may not equal year-to-date amounts due to rounding.

⁽¹⁾ Only select products are shown.⁽²⁾ Beginning in 2011, Merck changed the reporting for certain over-the-counter products. Sales of these products outside the United States were previously recorded in the Pharmaceutical business, and are now reported in the Consumer Care business. Prior period amounts have been recast on a comparative basis.⁽³⁾ Includes pharmaceutical products not individually shown above. Other Vaccine sales included in Other Pharmaceutical were \$54 million, \$67 million, \$100 million and \$62 million for the first, second, third and fourth quarters of 2011, respectively. Other Vaccine sales included in Other Pharmaceutical were \$55 million, \$57 million, \$94 million and \$75 million for the first, second, third and fourth quarters of 2010, respectively.⁽⁴⁾ Other revenues are primarily comprised of alliance revenue, miscellaneous corporate revenues and third party manufacturing sales.

MERCK & CO., INC.
FRANCHISE / KEY PRODUCT SALES
FOURTH QUARTER 2011
(AMOUNTS IN MILLIONS)

Table 3a

	Global			U.S.			International		
	4Q11	4Q10	% Change	4Q11	4Q10	% Change	4Q11	4Q10	% Change
TOTAL SALES⁽¹⁾	\$12,294	\$12,094	2	\$5,296	\$5,224	1	\$6,998	\$6,870	2
PHARMACEUTICAL⁽²⁾	10,755	10,441	3	4,606	4,384	5	6,149	6,057	2
Cardiovascular									
Zetia	640	629	2	327	329	-1	313	299	5
Vytorin	475	562	-16	213	296	-28	262	266	-2
Integrilin	57	63	-9	50	58	-13	7	5	31
Diabetes & Obesity									
Januvia	960	675	42	503	425	18	457	250	83
Janumet	386	288	34	193	164	18	193	123	56
Diversified Brands									
Cozaar / Hyzaar	427	415	3	20	9	*	407	406	
Zocor	111	121	-8	8	12	-33	103	109	-5
Propecia	117	124	-6	36	39	-8	81	85	-5
Claritin Rx	74	86	-14				74	86	-14
Remeron	59	62	-5	1	1	14	58	61	-5
Vasotec / Vaseretic	58	64	-9				58	64	-9
Proscar	52	44	18	1	1	8	51	43	18
Infectious Disease									
Isentress	387	313	24	193	164	18	194	149	30
PegIntron	175	198	-12	25	35	-28	150	163	-8
Cancidas	164	174	-6	12	17	-30	152	157	-3
Primaxin	119	158	-25	14	29	-50	104	130	-19
Invanz	110	113	-3	55	50	10	54	63	-13
Avelox	95	92	3	86	86	1	9	6	40
Noxafil	59	48	24	16	9	85	42	39	9
Crixivan / Stocrin	42	58	-28	1	2	-26	40	56	-28
Rebetol	36	54	-34				36	54	-34
Victrelis	87		*	58		*	29		*
Neurosciences & Ophthalmology									
Maxalt	178	149	20	132	106	24	46	43	8
Cosopt / Trusopt	117	131	-11	4	5	-28	113	126	-10
Oncology									
Temodar	230	266	-13	99	109	-10	132	157	-16
Emend	114	110	4	68	65	5	46	45	2
Intron A	51	54	-5	25	28	-10	26	26	1
Respiratory & Immunology									
Singular	1,461	1,349	8	957	838	14	504	511	-1
Remicade	511	710	-28				511	710	-28
Nasonex	325	303	7	163	146	12	161	157	3
Clarinx	129	138	-6	51	47	8	78	90	-14
Arcoxia	110	115	-4				110	115	-4
Simponi	61	42	45				61	42	45
Asmanex	57	53	7	51	47	8	6	6	4
Proventil	38	55	-31	35	53	-35	3	2	76
Dulera	37	6	*	36	6	*	1		*
Vaccines									
Gardasil	274	221	24	202	157	29	72	64	13
ProQuad, M-M-R II and Varivax	276	285	-3	243	272	-11	33	13	*
RotaTeq	195	169	15	162	149	9	33	21	57
Pneumovax	222	156	43	137	115	18	86	40	*
Zostavax	78	107	-27	73	107	-32	5		*
Women's Health & Endocrine									
Fosamax	211	234	-10	8	25	-69	204	209	-3
NuvaRing	168	145	16	102	86	18	66	58	12
Follistim AQ	126	138	-9	42	40	4	84	98	-14
Implanon	74	71	3	33	24	39	40	47	-15
Cerazette	69	49	42				69	49	42
Other Pharmaceutical⁽³⁾	953	1,044	-9	169	233	-28	784	811	-3
ANIMAL HEALTH	868	815	6	192	169	13	676	646	5
CONSUMER CARE⁽²⁾	361	381	-5	225	232	-3	136	149	-8
Claritin OTC	92	103	-11	59	65	-10	33	38	-14
Other Revenues⁽⁴⁾	310	457	-32	274	438	-38	37	19	97
Astra	256	302	-15	256	302	-15			

* 100% or greater

(1) Only select products are shown.

(2) In the first quarter of 2011, Merck changed the reporting for certain over-the-counter products. Sales of these products outside the United States were previously recorded in the Pharmaceutical business, and are now reported in the Consumer Care business. Prior period amounts have been recast on a comparative basis.

(3) Includes Pharmaceutical products not individually shown above. Other Vaccine sales included in Other Pharmaceutical were \$62 million and \$75 million on a global basis for fourth quarter 2011 and 2010, respectively.

(4) Other revenues are primarily comprised of alliance revenue, miscellaneous corporate revenues and third party manufacturing sales.

MERCK & CO., INC.
FRANCHISE / KEY PRODUCT SALES
FULL YEAR 2011
(AMOUNTS IN MILLIONS)

Table 3b

	Global			U.S.			International		
	Full Year 2011	Full Year 2010	% Change	Full Year 2011	Full Year 2010	% Change	Full Year 2011	Full Year 2010	% Change
TOTAL SALES ⁽¹⁾	\$48,047	\$45,987	4	\$20,495	\$20,226	1	\$27,552	\$25,761	7
PHARMACEUTICAL ⁽²⁾	41,289	39,267	5	17,117	16,748	2	24,172	22,519	7
Cardiovascular									
Zetia	2,428	2,297	6	1,223	1,227		1,205	1,070	13
Vytorin	1,882	2,014	-7	888	1,077	-18	994	938	6
Integrilin	230	266	-14	208	245	-15	22	20	7
Diabetes & Obesity									
Januvia	3,324	2,385	39	1,824	1,563	17	1,499	822	82
Janumet	1,363	954	43	712	576	24	651	378	72
Diversified Brands									
Cozaar / Hyzaar	1,663	2,104	-21	107	400	-73	1,555	1,705	-9
Zocor	456	468	-3	32	42	-22	423	426	-1
Propecia	447	447		134	148	-10	313	298	5
Claritin Rx	314	296	6				314	296	6
Remeron	241	223	8	6	7	-4	234	216	8
Vasotec / Vaseretic	231	255	-10				231	255	-10
Proscar	223	216	3	5	6	-17	218	210	4
Infectious Disease									
ISENTRESS	1,359	1,090	25	681	554	23	678	536	27
PegIntron	657	737	-11	71	98	-27	586	639	-8
Cancidas	640	611	5	44	61	-28	595	550	8
Primaxin	515	610	-16	87	123	-30	429	487	-12
Invanz	406	362	12	205	180	14	200	182	10
Avelox	322	316	2	288	296	-3	34	20	69
Noxafil	230	198	16	61	51	20	169	147	15
Crixivan / Stocrin	192	206	-7	5	8	-32	187	198	-6
Rebetol	174	221	-21	1	1	-13	173	220	-21
Victralis	140		*	98		*	43		*
Neurosciences & Ophthalmology									
Maxalt	639	550	16	451	378	19	187	173	9
Cosopt / Trusopt	477	484	-1	16	20	-19	461	464	-1
Oncology									
Temodar	935	1,065	-12	396	403	-2	538	662	-19
Emend	419	378	11	239	230	4	180	147	22
Intron A	194	209	-7	97	114	-14	97	95	1
Respiratory & Immunology									
Singular	5,479	4,987	10	3,536	3,219	10	1,942	1,768	10
Remicade	2,667	2,714	-2				2,667	2,714	-2
Nasonex	1,286	1,219	5	604	639	-6	682	580	18
Clarinet	621	623		197	203	-3	424	420	1
Arcoxia	431	398	8				431	398	8
Simponi	264	97	*				264	97	*
Asmanex	206	208	-1	185	195	-5	21	13	63
Proventil	155	210	-26	145	202	-28	10	8	30
Dulera	96	8	*	94	8	*	2		*
Vaccines									
Gardasil	1,209	988	22	880	722	22	329	266	24
ProQuad, M-M-R II and Varivax	1,202	1,378	-13	1,108	1,305	-15	94	73	29
RotaTeq	651	519	25	522	439	19	129	81	60
Pneumovax	498	376	33	350	296	18	148	80	85
Zostavax	332	243	37	320	243	32	12		*
Women's Health & Endocrine									
Fosamax	855	926	-8	45	93	-52	810	832	-3
NuvaRing	623	559	12	369	342	8	254	217	17
Follistim AQ	530	528		163	167	-2	367	361	2
Implanon	294	236	25	126	86	45	169	150	13
Cerazette	268	209	28				268	209	28
Other Pharmaceutical ⁽³⁾	3,521	3,879	-9	593	781	-24	2,928	3,098	-5
ANIMAL HEALTH	3,253	2,941	11	711	616	15	2,542	2,326	9
CONSUMER CARE ⁽²⁾	1,840	1,823	1	1,210	1,213		630	609	3
Claritin OTC	511	526	-3	363	379	-4	147	147	
Other Revenues ⁽⁴⁾	1,666	1,956	-15	1,457	1,649	-12	208	307	-32
Astra	1,184	1,252	-5	1,184	1,252	-5			

* 100% or greater

⁽¹⁾ Only select products are shown.

⁽²⁾ In the first quarter of 2011, Merck changed the reporting for certain over-the-counter products. Sales of these products outside the United States were previously recorded in the Pharmaceutical business, and are now reported in the Consumer Care business. Prior period amounts have been recast on a comparative basis.

⁽³⁾ Includes Pharmaceutical products not individually shown above. Other Vaccine sales included in Other Pharmaceutical were \$283 million and \$282 million on a global basis for full year 2011 and 2010, respectively.

⁽⁴⁾ Other revenues are primarily comprised of alliance revenue, miscellaneous corporate revenues and third party manufacturing sales.

MERCK & CO., INC.
PHARMACEUTICAL GEOGRAPHIC SALES
(AMOUNTS IN MILLIONS)

Table 3c

	1Q11	2Q11	3Q11	4Q11	Full Year	1Q10	2Q10	3Q10	4Q10	Full Year	% Change 4Q	% Change FY
TOTAL PHARMACEUTICAL	\$9,820	\$10,360	\$10,354	\$10,755	\$41,289	\$9,665	\$9,638	\$9,523	\$10,441	\$39,267	3	5
United States	3,907	4,088	4,515	4,606	17,117	4,072	4,026	4,265	4,384	16,748	5	2
% Pharmaceutical Sales	39.8%	39.5%	43.6%	42.8%	41.5%	42.1%	41.8%	44.8%	42.0%	42.7%		
Europe ⁽¹⁾	2,587	2,827	2,588	2,621	10,623	2,810	2,631	2,342	2,677	10,459	-2	2
% Pharmaceutical Sales	26.3%	27.3%	25.0%	24.4%	25.7%	29.1%	27.3%	24.6%	25.6%	26.6%		
Japan	1,164	1,104	1,114	1,327	4,709	811	902	855	1,077	3,645	23	29
% Pharmaceutical Sales	11.8%	10.7%	10.8%	12.3%	11.4%	8.4%	9.4%	9.0%	10.3%	9.3%		
Latin America	700	743	667	747	2,857	659	696	699	778	2,832	-4	1
% Pharmaceutical Sales	7.1%	7.2%	6.4%	6.9%	6.9%	6.8%	7.2%	7.3%	7.5%	7.2%		
Asia Pacific	699	779	763	736	2,977	561	622	618	702	2,503	5	19
% Pharmaceutical Sales	7.1%	7.5%	7.4%	6.8%	7.2%	5.8%	6.5%	6.5%	6.7%	6.4%		
China	187	206	220	221	834	133	159	145	173	611	28	37
Eastern Europe/Middle East Africa	358	369	371	378	1,476	375	395	353	393	1,516	-4	-3
% Pharmaceutical Sales	3.6%	3.6%	3.6%	3.5%	3.6%	3.9%	4.1%	3.7%	3.8%	3.9%		
Canada	360	399	285	279	1,323	337	328	374	364	1,403	-23	-6
% Pharmaceutical Sales	3.7%	3.9%	2.8%	2.6%	3.2%	3.5%	3.4%	3.9%	3.5%	3.6%		
Other	45	51	51	61	208	40	37	17	67	161	-9	29
% Pharmaceutical Sales	0.5%	0.5%	0.5%	0.6%	0.5%	0.4%	0.4%	0.2%	0.6%	0.4%		

(1) Europe primarily represents all European Union countries and the European Union accession markets.

MERCK & CO., INC.
EQUITY INCOME / JV SALES / OTHER (INCOME) EXPENSE - GAAP
FOURTH QUARTER 2011
AMOUNTS IN MILLIONS

Table 4

EQUITY INCOME FROM AFFILIATES

	4Q11	4Q10	Full Year 2011	Full Year 2010
ASTRAZENECA LP	\$ 256	\$ 190	\$ 574	\$ 546
Other ⁽¹⁾	1	(19)	36	41
TOTAL	\$ 257	\$ 171	\$ 610	\$ 587

⁽¹⁾ Primarily reflects results for Sanofi Pasteur MSD and Johnson & Johnson^oMerck Consumer Pharmaceuticals Company ("JJCPC"). In the third quarter of 2011, the company divested its interest in the JJCPC joint venture.

SANOFI PASTEUR MSD JOINT VENTURE SALES DETAIL

All sales reported here are end-market JV sales, presented on a "NET" basis.

	4Q11	4Q10	Full Year 2011	Full Year 2010
GARDASIL	\$ 70	\$ 106	\$ 253	\$ 350
FLU VACCINES	54	62	183	220
OTHER VIRAL VACCINES	28	27	105	93
ROTATEQ	12	9	44	42
HEPATITIS VACCINES	10	7	39	25
Other Vaccines	131	135	486	487
TOTAL SANOFI PASTEUR MSD SALES	\$ 305	\$ 346	\$ 1,110	\$ 1,217

OTHER (INCOME) EXPENSE, NET

	4Q11	4Q10	Full Year 2011	Full Year 2010
INTEREST INCOME	\$ (61)	\$ (27)	\$ (199)	\$ (83)
INTEREST EXPENSE	192	177	749	715
EXCHANGE LOSSES	41	130	143	214
Other, net ⁽¹⁾	(33)	29	253	458
TOTAL	\$ 139	\$ 309	\$ 946	\$ 1,304

⁽¹⁾ Other, net for the full year of 2011 includes a charge of \$500 million related to the resolution of the arbitration proceeding with Johnson & Johnson. Other, net for the full year of 2010 reflects a \$950 million legal reserve and \$443 million of income recognized upon AstraZeneca's asset option exercise.